The right treatment for the right patient with COPD: lessons from the IMPACT trial

Long-acting bronchodilators are the basis of treatment for COPD [1]; however, there are some patients who suffer from frequent or severe exacerbations, despite maximal bronchodilation [2]. These patients are at increased risk of death and represent a great challenge in clinical practice [3]. Inhaled corticosteroids (ICS) are the basis of the treatment of asthma and are also effective, albeit to a lesser extent, in some patients with COPD [4]. Generally speaking, ICS are indicated in patients with COPD and exacerbations, despite bronchodilator treatment [1].

Source: European Respiratory Journal - May 20, 2020 Category: Respiratory Medicine Authors: Stolz, D., Miravitlles, M. Tags: Editorials Source Type: research